Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
A phase 1/2 trial of APG-157 in glioma & glioblastoma, run by Aveta Biomics, Inc., now recruiting.
Overview
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab is a phase 1/2 interventional study registered as NCT06011109 by Aveta Biomics, Inc., with 30 participants planned, started 2023-12-13 and due to reach its primary completion in 2026-12-31. Interventions recorded: APG-157.
Similar pages
not linked directly; found by shared links- TrialSafety and Efficacy of APG-157 in Head and Neck Cancer
Shares Aveta Biomics and the tag pipeline.
- TrialMaximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Shares Glioma & glioblastoma and the tag pipeline.
- TrialA Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
Shares Glioma & glioblastoma and the tag pipeline.
- TrialA Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme
Shares Glioma & glioblastoma and the tag pipeline.
- TrialA Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
Shares Glioma & glioblastoma and the tag pipeline.
- TrialStudy of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
Shares Glioma & glioblastoma and the tag pipeline.
- TrialInjection of Active Allogeneic Natural Killer Cells in Patients With Gliomas
Shares Glioma & glioblastoma and the tag pipeline.
- TrialA Study of VRT106 for Injection in Patients With Recurrent/Progressive Glioblastoma
Shares Glioma & glioblastoma and the tag pipeline.